Navigation Links
Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
Date:1/7/2008

//studio-5.financialcontent.com/prnews?Page=Quote&Ticker=AVAN" onClick="var s=s_gi(s_account); var hd1 = document.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >AVAN) in October 2007.

"Fast Track status acknowledges CDX-110's potential to fill an unmet need for glioblastoma patients and gives it priority within the FDA," said Thomas Davis, M.D., Chief Medical Officer of Celldex Therapeutics. "Confirmation of the promising results we've already observed is a high priority at Celldex, as it is within the brain cancer community in general."

About CDX-110

CDX-110 is an investigational immunotherapy that targets the tumor specific molecule EGFRvIII, a functional variant of the epidermal growth factor receptor (EGFR), which is a protein that has been well validated as a target for cancer therapy. This particular variant, EGFRvIII occurs in about 40 percent of Glioblastoma Multiforme (GBM) patients. It was discovered in a collaborative effort between Dr. Bert Vogelstein and Dr Albert Wong at Johns Hopkins University and Dr. Darell Bigner at Duke University. Unlike EGFR, EGFRvIII is not present in normal tissues, suggesting this target will enable the development of a tumor-specific therapy for cancer patients. Furthermore, EGFRvIII is a transforming oncogene that can directly contribute to cancer cell growth. While originally discovered in GBM, the most common and aggressive form of brain cancer, the expression of EGFRvIII has also been observed in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head & neck cancers. Celldex has exclusive rights to EGFRvIII vaccines and is pursuing the development of CDX-110 for GBM therapy, as well as in other cancers through additional clinical studies.

About Fast Track Drug Designation

Under the FDA Modernization Act of 1997, designation as a Fast Track product for a new drug or biological products means that FDA will take such actio
'/>"/>

SOURCE Celldex Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015 The International Myeloma Foundation (IMF) – ... working toward prevention and a cure – today commended ... federal resolution (H. Res. 174) that supports the designation ... Myeloma Awareness Month." Currently there are more ... than 110,000 new cases are diagnosed yearly, according to ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 /PRNewswire/ ... specialty pharmaceutical and medical device company focused on ... primary and metastatic liver cancers, announces the reporting ... the Company,s Melphalan Hydrochloride for Injection with the ... therapies in a poster presentation at the Society of ...
(Date:3/26/2015)... Huntington Memorial Hospital is the first facility ... valve replacement (TAVR), a minimally invasive replacement of heart ... to replace an aortic valve without a chest incision ... The procedure is performed by a dedicated Huntington ... Durairaj , MD, interventional cardiologist and Robbin Cohen ...
Breaking Medicine Technology:The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... hip injuries is a growing field in orthopaedic medicine. ... with labral tear to confirm the pain etiology, research ... Medicine’s ( AOSSM ) Specialty Day suggests that pain ... outcomes following arthroscopic hip surgery. , “Our study ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... for patients with Type V AC joint injuries, according ... study, presented today at the American Orthopaedic Society for ... personnel returned to duty faster when surgery was not ... patients, with 7 receiving surgical treatment and 17 receiving ...
(Date:3/28/2015)... 2015 Andrew Hawley of Vintage Rock Posters ... concert posters. The Who and the Doors played together at ... 1968. According to Hawley, “The Who toured the United States ... college campuses. Perhaps the most famous Who poster was a ... the Doors on August 2, 1968 at the Singer Bowl ...
(Date:3/28/2015)... 28, 2015 Aureus Medical Group ... including physical therapy jobs, has announced that it ... Physical Therapy Association Annual Conference to be held ... Hotel in Columbus, OH. , The OPTA ... exhibits with products and services. , Representatives ...
(Date:3/28/2015)... The "Petrick Sustainable Health System" ... After 18 years of research and experience with patients ... Dr. Jon Petrick is excited to be launching his ... the immediate benefits of this radical new system are ... strength of the immune system, faster healing of injuries, ...
Breaking Medicine News(10 mins):Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2
... -- Mayo Clinic has clarified the methods of diagnosis ... vessel disease of the brain and spinal cord that ... system vasculitis (PCNSV) can best be identified through a ... cerebral arteries), brain biopsy and other laboratory studies. , ...
... Inc. (Nasdaq: PMTI ), a leading developer of ... cosmetic treatments, will hold its,quarterly conference call of its ... at 11:30AM Eastern Time. If you would like to,participate, ... on that,day. The telephone replay will be available one ...
... the World,s First Accurate Non-Contact Clinical Thermometer, ... a division of,American Scientific Resources, (ASFX-OTC) today announced ... first non-contact clinical,thermometer in the world, now available ... 5-in-1, made in Italy and long,recommended by doctors ...
... no proof they help children under 6, and they may ... -- Beginning Thursday, a panel of experts at the U.S. ... over-the-counter cough and cold medicines for young children. , Such ... the FDA, who published a 365-page review on the issue ...
... a leading provider,of business intelligence solutions that combine ... announced this week that its,longstanding client, Miller Children,s ... children,s hospitals named to the 2007 Leapfrog Top ... its outstanding,performance," said Swati Abbott, President of MEDai. ...
... the evidence shows no link , THURSDAY, Oct. 18 (HealthDay ... stretching before or after exercise will not prevent muscle soreness, ... 10 studies, each involving from 10 to 30 people. , ... laboratory settings, and the time spent stretching by participants varied ...
Cached Medicine News:Health News:Mayo Clinic clarifies diagnosis for serious blood vessel disease of brain and spinal cord 2Health News:Mayo Clinic clarifies diagnosis for serious blood vessel disease of brain and spinal cord 3Health News:Palomar Medical Technologies Third Quarter 2007 Financial Results Conference Call and Webcast 2Health News:Kidz-Med to Launch the Thermofocus(R) 5-in-1 Exclusively at Walgreens Stores Nationwide 2Health News:Kidz-Med to Launch the Thermofocus(R) 5-in-1 Exclusively at Walgreens Stores Nationwide 3Health News:FDA Panel Weighs Ban on Kids' Cold Medicines 2Health News:FDA Panel Weighs Ban on Kids' Cold Medicines 3Health News:FDA Panel Weighs Ban on Kids' Cold Medicines 4Health News:Leading Children's Hospital Utilizes MEDai's Solutions to Deliver Outstanding Care 2
... allows detection of SYBR Green I or ... range of fluorophores in the second channel ... for a multitude of applications such ... thermal cycler offers precision thermal control and ...
Inquire...
... SmartCycler System is a rapid, real-time thermal ... biological samples. By automating much of the ... individually programmable, it is the fastest, easiest ... on the market. The SmartCycler delivers highly ...
Chemically Resistant Sealing Mat for 96ch, 1.1ml or 2.0ml, Deep Well, Round Available Sterile...
Medicine Products: